Skip to main content
. 2023 Nov 7;44(3):487–497. doi: 10.1097/IAE.0000000000003980

Fig. 4.

Fig. 4.

Distribution of BCVA letter gain and loss by treatment group at Month 13. A. Approximately 55.0% of PBM-treated eyes showed ≥5 letter gain (mean of 9.7 letters, SD 3.7) compared with 40.8% of Sham, 26.4% of PBM-treated eyes showed ≥ 10 letter gain (mean of 12.8 letters, SD 2.7) compared with 14.9% of Sham, and 5.5% of PBM-treated eyes showed ≥ 15 letter gain compared with 1.9% of Sham. B. A higher number of Sham-treated and nonstudy eyes showed BCVA letter losses compared with PBM as noted in the −11 to −15, −6 to −10, and −1 to −5 letter loss groups. A higher number of PBM-treated eyes showed BCVA letter gains in the 5 to 9, 10 to 14, 15 to 19, and ≥ 20 letter gain groups. * Patient had vision loss because of worsening of posterior capsule opacity. BL, baseline.